Pin Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pin Wu has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Can Hu
Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
14 shared publications - Guofeng Chen
Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
14 shared publications - Han Liang
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
14 shared publications - Jia Qi
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
14 shared publications - Jian Chen
Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
14 shared publications - Jing Chen
Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
14 shared publications
Latest Publications
- Open Access
- 4 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (35) , e07647
PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC
Tissue‐resident memory CD4+ T cells (CD4+ TRMs) are pivotal in immune responses during inflammation and infection, yet their phenotype and function within the tumor microenvironment (TME) remain elusive. Here, we delineated CD4+ TRMs in non‐small cell lung cancer (NSCLC) using CD103 and CD69 as defining markers and demonstrated that their transcriptional and phenotypic profiles closely resembled those observed in murine models. Tumor‐infiltrating CD4+ TRMs exert helper antitumor effects by secreting the chemokine XCL1 to recruit conventional type 1 dendritic cells (cDC1s), facilitating antigen presentation and priming cytotoxic T lymphocyte responses. Mechanistically, we identified the costimulatory molecule JAML as essential for CD4+ TRM‐mediated cDC1 mobilization. Compared with their counterparts in normal lung tissue, tumor‐infiltrating CD4+ TRMs exhibited elevated expression of immune checkpoint molecules, indicating a dysfunctional state, accompanied by significantly reduced XCL1 expression. PD‐1 signaling within the NSCLC TME suppressed JAML expression—an effect reversible by PD‐1 blockade—while the administration of a JAML agonist further enhanced the antitumor efficacy of PD‐1 inhibitors in tumor‐bearing mice. Clinically, the presence of XCL1‐secreting CD4+ TRMs positively correlated with favorable clinical outcomes and enhanced responses to anti‐PD‐1 immunotherapy in NSCLC patients. Our findings reveal a critical role for JAML in facilitating CD4+ TRM‐mediated cDC1 mobilization within the NSCLC TME and highlight the translational potential of targeting CD4+ TRMs to enhance the efficacy of immune checkpoint blockade therapies.
- 4 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (35) , e07647
Open AccessPD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC
Tissue‐resident memory CD4+ T cells (CD4+ TRMs) are pivotal in immune responses during inflammation and infection, yet their phenotype and function within the tumor microenvironment (TME) remain elusive. Here, we delineated CD4+ TRMs in non‐small cell lung cancer (NSCLC) using CD103 and CD69 as defining markers and demonstrated that their transcriptional and phenotypic profiles closely resembled those observed in murine models. Tumor‐infiltrating CD4+ TRMs exert helper antitumor effects by secreting the chemokine XCL1 to recruit conventional type 1 dendritic cells (cDC1s), facilitating antigen presentation and priming cytotoxic T lymphocyte responses. Mechanistically, we identified the costimulatory molecule JAML as essential for CD4+ TRM‐mediated cDC1 mobilization. Compared with their counterparts in normal lung tissue, tumor‐infiltrating CD4+ TRMs exhibited elevated expression of immune checkpoint molecules, indicating a dysfunctional state, accompanied by significantly reduced XCL1 expression. PD‐1 signaling within the NSCLC TME suppressed JAML expression—an effect reversible by PD‐1 blockade—while the administration of a JAML agonist further enhanced the antitumor efficacy of PD‐1 inhibitors in tumor‐bearing mice. Clinically, the presence of XCL1‐secreting CD4+ TRMs positively correlated with favorable clinical outcomes and enhanced responses to anti‐PD‐1 immunotherapy in NSCLC patients. Our findings reveal a critical role for JAML in facilitating CD4+ TRM‐mediated cDC1 mobilization within the NSCLC TME and highlight the translational potential of targeting CD4+ TRMs to enhance the efficacy of immune checkpoint blockade therapies.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S2 shows characteristics summary of patients in the GC external validation cohort
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S2 shows characteristics summary of patients in the GC external validation cohort
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S1 shows clinicopathological correlations of m-TLSs in the GC H&E cohort
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S1 shows clinicopathological correlations of m-TLSs in the GC H&E cohort
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S5 shows characteristics of colorectal cancer patients in the flow cytometry cohort
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S5 shows characteristics of colorectal cancer patients in the flow cytometry cohort
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S4 shows characteristics summary of GC patients in the flow cytometry cohort
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S4 shows characteristics summary of GC patients in the flow cytometry cohort
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S1 shows model performance and clinical stratification metrics
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S1 shows model performance and clinical stratification metrics
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S2 shows spatial and maturation subtypes of TLSs and their clinical associations
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S2 shows spatial and maturation subtypes of TLSs and their clinical associations
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S4 shows interaction between CD8+ TRM and activated B cells in m-TLSs
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S4 shows interaction between CD8+ TRM and activated B cells in m-TLSs
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S3 shows biological patterns of TRM in TLSs in gastric cancer
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S3 shows biological patterns of TRM in TLSs in gastric cancer
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Tertiary lymphoid structures (TLS) are critical components of the tumor microenvironment in gastric cancer, but clinical assessment of TLSs is challenging. The development of automated annotation tools for histopathologic slide analysis could facilitate the identification of TLSs and enhance our understanding of the mechanisms driving TLS maturation. In this study, we generated a transformer-based deep learning model that enables quantitative characterization of TLS maturity from whole-slide images. Application of the model to a large gastric cancer cohort (n = 253) showed that higher TLS maturity correlated with improved patient survival. Integration of single-cell RNA sequencing data from 17 patients with gastric cancer combined with multiplex IHC, flow cytometry, and functional coculture assays identified a key immune circuit in mature TLSs involving CD8+ tissue-resident memory T cells, which recruit activated B cells via the CXCL13–CXCR5 axis to enhance tissue-resident memory T-cell cytotoxicity through granzyme B upregulation. Overall, this study established a clinically applicable artificial intelligence tool and uncovered key immune interactions that regulate TLS maturation and antitumor immunity in gastric cancer.Significance:A deep learning model demonstrates that higher tertiary lymphoid structure maturity predicts improved gastric cancer patient survival and identifies a key immune circuit, offering a clinically applicable tool that could guide treatment.This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Tertiary lymphoid structures (TLS) are critical components of the tumor microenvironment in gastric cancer, but clinical assessment of TLSs is challenging. The development of automated annotation tools for histopathologic slide analysis could facilitate the identification of TLSs and enhance our understanding of the mechanisms driving TLS maturation. In this study, we generated a transformer-based deep learning model that enables quantitative characterization of TLS maturity from whole-slide images. Application of the model to a large gastric cancer cohort (n = 253) showed that higher TLS maturity correlated with improved patient survival. Integration of single-cell RNA sequencing data from 17 patients with gastric cancer combined with multiplex IHC, flow cytometry, and functional coculture assays identified a key immune circuit in mature TLSs involving CD8+ tissue-resident memory T cells, which recruit activated B cells via the CXCL13–CXCR5 axis to enhance tissue-resident memory T-cell cytotoxicity through granzyme B upregulation. Overall, this study established a clinically applicable artificial intelligence tool and uncovered key immune interactions that regulate TLS maturation and antitumor immunity in gastric cancer.Significance:A deep learning model demonstrates that higher tertiary lymphoid structure maturity predicts improved gastric cancer patient survival and identifies a key immune circuit, offering a clinically applicable tool that could guide treatment.This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.